CVS Caremark 2013 Drug Trend Report |
10. The Cost of Specialty Drugs Is “Going Through The Roof” With No End In Sight
9. Specialty Distribution Networks Are Expanding To Allow for Greater Access And Control of Specialty Drugs
8. Biosimilars Are Coming; The First Is Poised For FDA Approval
7. Health Care, As A Whole, Is Evolving Into A Pay-For-Performance Marketplace
6. Growing Adaptation Of Data Analytics Will Improve Patient Outcomes
5. Poor Patients Continue To Flood The Specialty Space Through PPACA
4. As Drug Costs Go Up, Adherence Goes Down Thus Hospital Spend Increases
3. The Marriage Of PBMs And Specialty Pharmacy Continues To Strengthen
2. Specialty Drug Manufacturers Continue To Limit Distributors For Margin Protection
1. Cost Will Be Weighed Against The Outcome Not Hyperbole